BTL Industries has received clearance from the United States Food and Drug Administration for a new indication of its EMFACE® device: the treatment of temporomandibular joint (TMJ) dysfunction. The newly cleared use allows dental and oral health providers to offer EMFACE for relief of symptoms associated with muscle spasm, TMJ-related pain, muscle re-education, increased local blood flow, and the maintenance or improvement of mandibular range of motion.
According to the company, EMFACE uses synchronized radiofrequency and high-intensity facial electrical stimulation (HIFES®) to stimulate facial muscles. The platform is designed to deliver results without the use of surgery, injections, or medication.
“EMFACE is an established technology platform with multiple FDA-cleared uses,” said David Chmel, CEO of BTL Industries. “This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction within its approved uses, expanding the benefits of EMFACE to more patients.”
“TMJ dysfunction impacts more than the jaw — it affects quality of life,” said Shireen Dhanani, DMD, Leesburg, Florida. “With EMFACE, we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care.”
BTL Industries develops technologies used across medical disciplines, including dentistry, dermatology, orthopedics, and rehabilitation. Founded in 1993, the company operates in over 90 countries and holds more than 200 patents.
More information about EMFACE is available at www.emface.com.
